Not So Fast
Healthy collaboration brings industry experts together to help businesses achieve their missions. When you collaborate with the right partners, the results will exceed your expectations. For example, a meaningful collaboration that is occurring is that of cardiovascular medicine and a federal regulatory authority, namely the FDA.
For close to 20 years, many professionals and laypersons have pushed forth the theory of ingesting low-dosages of aspirin to prevent cardiovascular problems, including heart attacks and strokes. But not so fast, for recently, the FDA has stated that everyone needs to understand there is no one size fits all cure as it relates daily aspirin dosages.
The FDA does support the research that low-dose aspirin can prevent "reoccurring" cardiovascular problems, but confirming aspirin can prevent the very first episode needs further evidence-based research.
As medical biologists, we know that aspirin, like other blood thinning medications, for such as Coumadin (warfarin), Pradaxa and others, interferes with the blood's clotting action, thereby reducing the potential for clots to develop and obstruct the flow of blood and oxygen.
The FDA suggests that pharmaceutical manufacturers collaborate with clinical life scientists to conduct additional scientific studies to confirm and support with data the beneficial affects of aspirin to prevent cardiovascular events. In the meantime, the federal agency is encouraging the public to consult with their individual primary physicians regarding a daily low-dose aspirin regime to ensure that ongoing ingestion is not contraindicative with other medicines and does not cause other health risks.